Add Formweb to your mobile device
System Formulary Update
Methylphenidate Extended Release Therapeutic Interchange
Situation
The therapeutic interchange for any BX-rated methylphenidate ER to AB-rated methylphenidate ER was approved for modification at the System Pharmacy and Therapeutics Committee meeting.
Background
The following therapeutic interchange was reviewed: BX-rated products are manufactured by SpecGx, Lannett, and Kremers/Mallinckrod; AB-rated methylphenidate extended-release products: Methylphenidate ER 18 mg (Dr. Reddy's, Trigen, Camber), Methylphenidate ER 27 mg (Mylan, Trigen, Camber), Methylphenidate ER 36 mg (Mylan, Trigen, Camber), Methylphenidate ER 54 mg (Trigen, Camber, Dr. Reddy's)
Assessment/ Recommendations:
System P&T voted to add the following formulary therapeutic interchange for the ordered medication.
|
From |
To |
|
Any BX-rated methylphenidate extended-release generic. |
Any AB-rated methylphenidate extended-release generic at same strength and frequency. |
Formulary/Epic changes will Go-Live on Tuesday, March 19, 2023.